Clinical Monitoring
Experienced clinical research associates who safeguard your participants and the integrity of your data, delivering risk-based monitoring to the standard expected in both local and global multinational studies.
Monitoring provides the sponsor with assurance that a study is being conducted as intended: that participants have given valid consent, that their safety is protected, that the protocol is observed, and that the database faithfully reflects what occurred at the site. Our monitors act as your representatives at every site.
Our clinical research associates are trained in ICH E6 (R3) and experienced in both local studies and global multinational programmes conducted under sponsors’ own procedures. They understand the protocol, they know the investigators, and they anticipate what an auditor or inspector will examine.
We apply a risk-based approach. On-site visits, remote review and centralised monitoring of data in Insight EDC are combined within one plan, concentrating effort on critical data and processes and detecting deficiencies early rather than at study close.

Monitoring calibrated to the risk profile of your study
Our clinical research associates integrate on-site, remote and centralised monitoring within a single risk-based strategy, directing oversight to the data and processes that matter most.
Risk assessment and monitoring plan
A documented assessment of the critical data and processes in your study, translated into a monitoring plan that defines the frequency, depth and modality of every visit.
Site qualification visits
Pre-study visits confirming that each site has the patient population, personnel, facilities and systems the protocol demands.
Site initiation visits
Comprehensive training of the site team on the protocol, GCP, safety reporting, investigational product handling and Insight EDC before recruitment opens.
Routine on-site monitoring
Scheduled visits to verify source data, review consent and essential documents, confirm protocol compliance and support the investigator team.
Remote and centralised monitoring
Ongoing review of data in Insight EDC between visits to detect trends, outliers, missing data and emerging site risks without waiting for the next visit.
Source data verification and review
Targeted verification of critical data against medical records, and evaluation of source documentation for quality, completeness and consistency.
Safety oversight
Assurance that adverse events and serious adverse events are identified, documented and reported within regulatory timelines.
Investigational product accountability
Verification of storage conditions, temperature records, dispensing, returns and reconciliation of investigational product at every site.
Co-monitoring and oversight visits
Joint visits with sponsor representatives, and independent oversight of monitoring conducted by other providers when a second perspective is required.
Close-out visits
Final reconciliation of data, documentation and investigational product, and formal closure of each site.
Audit and inspection readiness
Preparation of sites ahead of sponsor audits and authority inspections, and support in addressing any resulting observations.
A disciplined monitoring cycle at every site
- 01
Plan
We evaluate the risks inherent in the study and agree the monitoring strategy with you before the first site is activated.
- 02
Prepare
Ahead of each visit, the monitor reviews the site’s data, outstanding queries, deviations and prior findings, and shares a structured agenda with the site.
- 03
Visit
On site or remotely, the monitor verifies critical data, reviews documentation and consent, inspects investigational product and meets the investigator.
- 04
Report
A comprehensive visit report and follow-up letter document each finding, the corrective action agreed and the responsible party.
- 05
Resolve
Every action is tracked through to closure. Any matter affecting participant safety or data integrity is escalated to you immediately.
- 06
Adapt
Monitoring intensity evolves with the study, increasing at sites showing emerging risk and reducing where quality is consistently high.
Complete visibility across every site
Our reporting keeps you continuously informed of site performance and maintains a state of readiness for any audit or inspection.
- 01
Monitoring plan
The agreed strategy for each site and each visit type, maintained throughout the study.
- 02
Visit reports and follow-up letters
Issued promptly after every visit, setting out findings, actions and responsibilities.
- 03
Issue and deviation tracking
A current log of outstanding actions and protocol deviations across all sites, with their status.
- 04
Site performance summaries
Recruitment, data entry, query and safety indicators for each site within your regular progress reports.
- 05
Inspection-ready files
Investigator site files and the trial master file kept complete and current from the first visit to the last.
Monitoring to local and global expectations
Our monitors apply the same rigour whether the study is conducted locally or forms part of a global multinational programme.
- 01
ICH E6 (R3) Good Clinical Practice
Including its risk-based approach to quality management and monitoring.
- 02
Egyptian Drug Authority requirements
National expectations for clinical trial monitoring, safety reporting and inspections.
- 03
Sponsor SOPs and global monitoring plans
In multinational studies, we operate within your procedures and systems alongside our own.
- 04
Declaration of Helsinki
The rights, safety and wellbeing of participants take precedence at every visit.
More from our clinical research team
Clinical Studies Management
Our flagship full-service offering, from feasibility to the final clinical study report.
Protocol Development
Protocols, consent forms and essential study documents designed for approval and flawless execution.
Site Selection and Management
Rigorously selected investigators and sites, supported from feasibility to close-out.
Data Management and Biostatistics
Validated data on Insight EDC and statistical analysis that withstands scrutiny.
Medical Writing
Clinical, regulatory and publication documents of the highest scientific standard.
